Quick answer
J0881
What Medicare pays for Aranesp (2026 Q3)
Once a claim carries a covered diagnosis, Medicare Part B reimburses the drug at the ASP + 6% payment limit. Current allowed amounts per billing unit:
| HCPCS | Description | Per unit | Allowed (ASP + 6%) |
|---|---|---|---|
| J0881 | Darbepoetin alfa, non-esrd | 1 mcg | $2.920 |
Source: CMS ASP Drug Pricing File, 2026 Q3. Payment = ASP + 6% per unit; multiply by units billed (watch JZ/JW wastage). Your patient's share is typically 20% after the deductible. Estimate the full cost & patient out-of-pocket →
Worked billing example for Aranesp
A concrete, paste-checkable example using J0881’s own billing-unit basis and vial sizes — not a hypothetical.
| Scenario | CIA fixed dose — 500 mcg SC every 3 weeks (70 kg reference patient) |
| Dose administered | 500 mcg |
| Billing unit basis | 1 unit = 1 mcg |
| Billing units (dose ÷ unit basis, rounded up) | 500 units of J0881 |
| Vial combination drawn (min-waste plan) | 1 × 500 mcg vial |
| Discarded (waste) | None |
| Wastage modifier (JW / JZ) | Bill all 500 units on a single line with JZ (attests zero drug discarded). What JZ/JW mean → |
| Medicare allowable (ASP + 6%, 2026 Q3) | 500 units × $2.920/unit = $1460.00 |
This is Medicare’s allowable payment limit (ASP + 6%, 2026 Q3) — not a promise of what you will be paid. Actual paid amount depends on sequestration and whether the claim carries a covered diagnosis.
Dose source: drugs/aranesp.html — "Worked example — CIA fixed dose, 70 kg patient": 500 mcg q3w fixed dose during chemo (single 500 mcg PFS, no waste). Different dose or drug? Compute your own dose → or estimate the full cost & patient out-of-pocket →.
Aranesp is a physician-administered biologic billed under Medicare Part B (not the Part D pharmacy benefit). Under Part B, Medicare pays the practice for the drug (HCPCS J0881) plus its administration — but only when the claim's diagnosis (ICD-10) code supports medical necessity. Each MAC publishes the specific covered diagnoses in a Billing & Coding Article; a claim with a diagnosis outside that list is typically denied as not medically necessary (CO-50).
Covered ICD-10 diagnoses for Aranesp
The 5 ICD-10 codes below are the FDA-approved indications for J0881 — the labeled uses Medicare generally pays for under medical necessity — grouped by condition. Use the filter to find a specific code or condition.
Anemia of CKD — 1 diagnoses (applies to J0881)
Blood, blood-forming organs & immune disorders (1)
| ICD-10 | Covered diagnosis |
|---|---|
| D63.1 | Anemia in chronic kidney disease |
Anemia of Malignancy — 1 diagnoses (applies to J0881)
Blood, blood-forming organs & immune disorders (1)
| ICD-10 | Covered diagnosis |
|---|---|
| D63.0 | Anemia in neoplastic disease |
Anemia NOS — 1 diagnoses (applies to J0881)
Blood, blood-forming organs & immune disorders (1)
| ICD-10 | Covered diagnosis |
|---|---|
| D64.9 | Anemia, unspecified |
ESRD — 1 diagnoses (applies to J0881)
Diseases of the genitourinary system (1)
| ICD-10 | Covered diagnosis |
|---|---|
| N18.6 | End stage renal disease |
Chemotherapy-Induced Anemia — 1 diagnoses (applies to J0881)
Blood, blood-forming organs & immune disorders (1)
| ICD-10 | Covered diagnosis |
|---|---|
| D64.81 | Anemia due to antineoplastic chemotherapy |
How to use this list when billing
Put a medically necessary, FDA-indicated diagnosis from the list above on the claim line with J0881, match the correct product code and units (check JZ/JW wastage), and document medical necessity. Because there's no drug-specific LCD, coverage is judged per medical necessity by your MAC; an off-label use can still be covered if supported by an approved drug compendium.
LCD vs. Billing & Coding Article vs. NCD
An LCD (Local Coverage Determination) is a MAC's policy on whether a service is reasonable and necessary in its region, and its companion Billing & Coding Article holds the covered ICD-10 and HCPCS code lists. A NCD (National Coverage Determination), where one exists, applies nationwide. Aranesp has no drug-specific LCD or Article, so there is no published covered-code list — it's covered under the general Part B drug benefit per medical necessity, and the FDA-approved indications above are the practical starting point.
Common Aranesp denial reasons
| What you see | Why | Fix |
|---|---|---|
| CO-50 — not medically necessary | Diagnosis the MAC doesn’t accept as medically necessary | Bill a medically necessary FDA-indicated diagnosis from the list above; document necessity (compendium cite for off-label) |
| Diagnosis/units mismatch | Right dx but wrong product code or unit count | Match the J/Q code and units to the drug actually given (check JZ/JW wastage) |
| Off-label denial | Indication isn't FDA-labeled and isn't compendium-supported | Cite an approved compendium (e.g. DrugDex/NCCN) or appeal with literature |
| Self-administered (SAD) denial | Drug is on your MAC's self-administered exclusion list | Check the SAD list — it may be Part D, not Part B |
Frequently asked questions
- Is Aranesp covered by Medicare?
- Yes. Aranesp (J0881) is covered under Medicare Part B as a physician-administered drug when billed for a medically necessary indication. There is no drug-specific Local Coverage Determination (LCD) for it, so coverage is determined per medical necessity by your MAC; the FDA-approved indications below are the starting point.
- What diagnoses are covered for Aranesp (J0881)?
- Medicare does not publish a drug-specific covered-diagnosis list for J0881. The 5 ICD-10 codes on this page are the FDA-approved indications — the labeled uses Medicare will generally pay for under medical necessity. Off-label uses may be covered if supported by an approved compendium.
- Which Medicare policy covers Aranesp?
- No drug-specific LCD or Billing & Coding Article exists for Aranesp. It's covered under the general Medicare Part B drug benefit per medical necessity, as judged by your Medicare Administrative Contractor (MAC).
- Why was my Aranesp claim denied as not medically necessary?
- The most common cause is a diagnosis the MAC doesn't consider medically necessary for J0881. Bill a covered/FDA-approved indication from the list below, document medical necessity, and confirm any local guidance with your MAC.
Related references
Covered is only half the answer.
You know the diagnosis is payable. Now quote the patient before the visit and catch underpayments: get Aranesp's exact Medicare allowed amount, your payer's rate vs. ASP+6%, and the patient's out-of-pocket — in about 30 seconds, free.
Estimate Aranesp cost & patient owe →Source & verification
- Source
- FDA-approved indications (Drugs@FDA labeling) mapped to ICD-10-CM. No drug-specific Medicare LCD/Article exists for Aranesp — Part B coverage is determined per medical necessity by your MAC.
- CMS article last revised
- n/a — the most recent revision CMS has published for this article.
- Page last reviewed by CareCost
- Jul 23, 2026 (coverage data retrieved 2026-07-23; we re-verify against CMS quarterly).
- Code licensing
- ICD-10-CM codes are public domain (CMS/CDC). CPT® codes are AMA-copyrighted and are intentionally not listed here — see the administration-code reference for those.
- Not advice
- This is general billing reference, not legal or billing advice. Always verify against the LCD/Article that applies to your MAC and patient.
- How we build this
- Compiled programmatically from the CMS Coverage API under a founder-led methodology maintained by Erin Rose (Founder), and reviewed against the source article with a practitioner-correction loop. See our methodology and editorial policy.
- Spotted an error?
- Email editorial@carecostestimate.com.